Haleon plc (NYSE:HLN) Shares Sold by Cohen Klingenstein LLC

Cohen Klingenstein LLC trimmed its holdings in shares of Haleon plc (NYSE:HLN) by 24.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 90,292 shares of the company’s stock after selling 29,750 shares during the period. Cohen Klingenstein LLC’s holdings in Haleon were worth $746,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cardinal Capital Management increased its stake in Haleon by 2.5% during the 2nd quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock worth $382,000 after buying an additional 1,140 shares in the last quarter. Pinnacle Bancorp Inc. grew its stake in Haleon by 29.8% during the 1st quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock worth $53,000 after purchasing an additional 1,421 shares in the last quarter. Blue Barn Wealth LLC raised its holdings in shares of Haleon by 7.3% in the 4th quarter. Blue Barn Wealth LLC now owns 20,858 shares of the company’s stock valued at $172,000 after purchasing an additional 1,425 shares in the last quarter. Defined Wealth Management LLC lifted its stake in Haleon by 5.8% during the first quarter. Defined Wealth Management LLC now owns 29,009 shares of the company’s stock worth $246,000 after purchasing an additional 1,590 shares during the last quarter. Finally, Confluence Investment Management LLC increased its stake in Haleon by 2.0% in the second quarter. Confluence Investment Management LLC now owns 83,694 shares of the company’s stock valued at $691,000 after purchasing an additional 1,623 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HLN. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Berenberg Bank initiated coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, HSBC assumed coverage on Haleon in a report on Wednesday, April 17th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

Haleon Price Performance

HLN traded down $0.09 on Monday, hitting $9.72. 6,133,514 shares of the company were exchanged, compared to its average volume of 5,239,349. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $9.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 0.73 and a current ratio of 1.04. The firm has a market capitalization of $44.38 billion, a P/E ratio of 32.40, a price-to-earnings-growth ratio of 2.69 and a beta of 0.24. The business’s fifty day moving average is $8.80 and its 200 day moving average is $8.49.

Haleon (NYSE:HLN) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $3.50 billion during the quarter, compared to analysts’ expectations of $3.55 billion. Haleon had a return on equity of 19.85% and a net margin of 9.71%. During the same quarter in the prior year, the firm earned $0.08 earnings per share. As a group, sell-side analysts anticipate that Haleon plc will post 0.47 EPS for the current year.

Haleon Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Thursday, September 19th. Shareholders of record on Friday, August 16th will be given a dividend of $0.0514 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, August 16th. Haleon’s payout ratio is 33.33%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.